(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

weight loss programs

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss […]

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down

March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023

Sept. 24, 2024 Marketdata LLC, DietBusinessWatch.com’s parent), estimates that the top competitors in the U.S. weight loss market lost at least $971 million in revenues last year, due to the juggernaut of GLP-1 medications. This is a huge transfer of sales from commercial and retail weight loss programs and product segments to medical programs. Here’s

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023 Read More »

Scroll to Top